Case series on multimodal endoscopic therapy for gastric antral vascular ectasia, a tertiary center experience

Table 1 Patient demographics, medical history and gastric antral vascular ectasia characteristics

Patient	Age	Sex	Race	GAVE associated conditions	Description	Biopsy confirmed?	ASA	On anticoagulation?	Sedation used	MELD-Na
1	65	F	W	Cirrhosis	Watermelon	N	3	No	MAC	15
2	58	M	W	Cirrhosis	Watermelon	N	3	Yes	MAC	17
3	75	F	B	LVAD	Watermelon	Y	4	No	MAC	n/a
4	55	M	W	Cirrhosis, DM	Nodular	N	3	No	MAC	15
5	79	F	W	Hypothyroidism	Watermelon	Y	3	No	MAC	n/a
6	65	F	W	Cirrhosis	Nodular	Y	3	No	MAC	11
7	70	F	B	Hypothyroidism	Watermelon	Y	2	No	MAC	n/a
8	53	M	W	Cirrhosis	Watermelon	N	3	No	MAC	26
9	70	M	W	DM	Diffuse	N	4	Yes	MAC	n/a
10	46	F	W	CKD	Nodular	Y	3	No	MAC	n/a
11	60	M	W	DM	Watermelon	N	4	No	MAC	n/a
12	68	F	W	Cirrhosis, DM	Watermelon	N	3	No	MAC	18
13	59	M	W	Cirrhosis, DM	Nodular	N	2	No	MAC	14
14	62	M	W	Cirrhosis, DM, LVAD	Nodular	N	4	Yes	MAC	25
15	58	M	W	Cirrhosis, DM	Nodular	Y	3	No	MAC	23

GAVE: Gastric antral vascular ectasia; F: Female; M: Male; LVAD: Left ventricular assist device; DM: Diabetes mellitus; CKD: Chronic kidney disease; Y: Yes; N: No; ASA: American Society of Anesthesiologists score; MAC: Monitored Anesthesia Care; MELD-Na: Model for end-stage liver disease–with sodium.